Gynécologie ASCORDIA01 ADNEXMR Scoring System: Impact of an MR Scoring System on Therapeutic Strategy of Pelvic Adnexal Masses Paris, Saint-Cloud CAROLINE MALHAIRE, ROMAN ROUZIER
Sein métastatique RH+ SAFIR-TOR Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women. Paris, Saint-Cloud PAUL-HENRI COTTU
Recherches "plusieurs pathologies" SHIVA02 (IC 2016-06) Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control. Paris, Saint-Cloud CHRISTOPHE LE TOURNEAU
Gynécologie - Endomètre ENDOLA A Phase I/II Trial to Assess the Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Recurrent Advanced/Metastatic Endometrial Cancer Patients Paris MANUEL RODRIGUES
Recherches "plusieurs pathologies" CHECK'UP Prospective Cohort Study to Identify the Predictive Factors of Response to PD-1 or PD-L1 Antagonists. Paris
Sein Néoadjuvant ALIENOR Detection of Circulating Tumoral DNA Mutations (Sequential Assessment) Following Neoadjuvant Chemotherapy for Breast Cancer: Clinical Validity (ALIENOR Study) Paris, Saint-Cloud
Appareil pulmonaire BP40657 A TWO-PART PHASE Ib/II STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF ATEZOLIZUMAB SUBCUTANEOUS IN PATIENTS WITH STAGE IV;NONÀSMALL CELL LUNG CANCER Paris
Recherches "plusieurs pathologies" MS1000070-176 An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies Paris
Sein métastatique RH+ HerSeq (PUMA-NER-9501) HER-Seq: A Blood-based Screening Study to Identify Patients with HER2 Mutations for;Enrollment into Clinical Research Studies of Neratinib Paris, Saint-Cloud
Sein métastatique triple négatif SYNERGY A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer. Paris